NCT07227402 2026-04-17
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
23 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03866382 2026-04-16
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05663710 2026-04-16
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06835972 2026-04-09
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07293351 2026-03-31
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT07077161 2026-01-28
SKIPPY 2
Leiden University Medical Center
Phase 2 Recruiting
NCT05092373 2026-01-14
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05263050 2025-12-03
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT05931393 2025-10-10
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07028125 2025-10-07
CANIQOL
Centre Francois Baclesse
Phase 4 Recruiting
NCT06934057 2025-09-24
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4 Recruiting
NCT05361720 2025-07-23
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT05127824 2025-05-04
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04322955 2025-04-25
Cyto-KIK
Columbia University
Phase 2 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT06548867 2024-08-12
CABOGEN
Gruppo Oncologico Italiano di Ricerca Clinica
Recruiting